Effect of Autograft CD34+ Dose on Outcome in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplant for Central Nervous System Tumors
Tristan Knight(Wayne State University), Gregory A. Yanik(University of Michigan), Michael A. Pulsipher(Primary Children's Hospital), Kasiani C. Myers(Immune Deficiency Foundation), Seth J. Rotz(Cleveland Clinic), Ellen Fraint(Memorial Sloan Kettering Cancer Center), Muna Qayed(Emory University), Kirsten M. Williams(National Institutes of Health), Mary Eapen(Medical College of Wisconsin), Hasan Hashem(Nationwide Children's Hospital), Rasha Atshan(Medical College of Wisconsin), Christopher C. Dvorak(University of California, San Francisco), Kirk R. Schultz(University of British Columbia), Hemalatha G. Rangarajan(Nationwide Children's Hospital), Baldeep Wirk(Boston University), Akshay Sharma(St. Jude Children's Research Hospital), Carrie L. Kitko(Vanderbilt University Medical Center), Kyle Hebert(Harvard University), Nahal Lalefar(University of California, San Francisco), Kanhatai Chiengthong(Thai Red Cross Society), Jeffery J. Auletta(Nationwide Children's Hospital), Larisa Broglie(Morgan Stanley Children's Hospital), Kwang Woo Ahn(Medical College of Wisconsin), Anne B. Warwick(Uniformed Services University of the Health Sciences), Donna A. Wall(University of Manitoba)
Cited by 3
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
|Transplantation and Cellular Therapy|2020|718
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
|Nature Medicine|2018|577